Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-23T20:00:10.518Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients

Published online by Cambridge University Press:  11 April 2011

Leonardo Tondo  and
Ross J. Baldessarini
Get access Rights & Permissions [Opens in a new window]

Abstract

We reviewed available research findings, including meta-analyses on effects of lithium-treatment associated with rates of suicidal behavior in bipolar disorder or unipolar major depressive disorder patients, and for comparisons of lithium to mood-stabilizing anticonvulsants. Data from meta-analyses consistently indicate marked reductions of suicidal behavior and mortality during long-term treatment with lithium salts in bipolar disorder patients, and possibly also in unipolar, recurrent major depressive, perhaps even more effectively than with anticonvulsants proposed as mood-stabilizers. Suicidal risk is frequently associated with dysphoric-agitated symptoms, anger, aggression, and impulsivity-all of which may respond better to treatment with lithium or other mood-stabilizing medicines than to antidepressants. In these conditions, antidepressant treatment may not provide a beneficial effect on risk of suicidal thoughts and perhaps attempts, particularly in juveniles, whereas, lithium, perhaps even more than anticonvulsants, seems to be remarkably effective in the preventing suicidal behavior. The mechanism of action is not well defined and may be associated with either a prevention of mood recurrences or a more specific “antisuicidal” activity.

Declaration of Interest: Dr. Tondo has received research support from Janssen and Eli Lilly Corporations and has served as a consultant to Glaxo-SmithKline and Merck Corporations. Dr. Baldessarini has recently been a consultant or investigator-initiated research collaborator with: AstraZeneca, Auritec, Biotrofix, Janssen, JDS-Noven, Lilly, Luitpold, NeuroHealing, Novartis, Pfizer, and SK-BioPharmaceutical Corporations. Neither author is a member of pharmaceutical speakers’ bureaus, nor do they or any family member hold equity positions in biomedical or pharmaceutical corporations.

Type
Editorials
Information
Epidemiology and Psychiatric Sciences , Volume 18 , Issue 3 , September 2009 , pp. 179 - 183
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Ahrens, B. & Müller-Oerlinghausen, B. (2001). Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 34, 132–136.Google Scholar
Akiskal, H.S., Benazzi, F., Perugi, G. & Rihmer, Z. (2005). Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. Journal of Affective Disorders 85, 245–258.CrossRefGoogle ScholarPubMed
Angst, J., Angst, F., Gerber-Werder, R. & Gamma, A. (2005). Suicide in 406 mood-disorder patients with and without long-term medication: a 40–44 years follow-up. Archives of Suicide Research 9, 279–300.CrossRefGoogle Scholar
Baldessarini, R.J. & Tondo, L. (2008). Lithium and suicidal risk. Bipolar Disorders 10, 114–115.CrossRefGoogle ScholarPubMed
Baldessarini, R.J. & Tondo, L. (2009). Suicidal risks during treatment of bipolar disorder patients with lithium versus anticonvulsants. Pharmacopsychiatry 42, 72–75.CrossRefGoogle ScholarPubMed
Baldessarini, R.J., Salvatore, P., Tohen, M., Khalsa, H.M.K. & Hennen, J. (2004). Morbidity from onset in first-episode bipolar I disorder patients: The International-300 study. Neuropsychopharmacology 29, Suppl. 1, S88.Google Scholar
Baldessarini, R.J., Pompili, M., Tondo, L., Tsapakis, E., Soldani, F., Faedda, G.L. & Hennen, J. (2005). Antidepressants and suicidal behavior: are we hurting or helping? Clinical Neuropsychiatry 2, 73–75.Google Scholar
Baldessarini, R.J., Tondo, L., Davis, P., Pompili, M., Goodwin, F.K. & Hennen, J. (2006). Decreased suicidal risk during long-term lithium treatment: meta-analysis. Bipolar Disorders 8, 625–639.CrossRefGoogle Scholar
Baldessarini, R.J., Tondo, L., Strombom, I., Dominguez, S., Fawcett, J., Oquendo, M., Tollefson, G.D., Valuck, R.J. & Tohen, M. (2007). Ecological studies of antidepressants and suicide risks. Harvard Review of Psychiatry 15, 133–145.Google Scholar
Baldessarini, R.J., Vieta, E., Calabrese, J.R., Tohen, M. & Bowden, C. (in press). Bipolar depression: overview and commentary. Harvard Review of Psychiatry.Google Scholar
Barbui, C., Esposito, E. & Cipriani, A. (2009). Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal 180, 291–297.CrossRefGoogle ScholarPubMed
Bowden, C.L., Calabrese, J.R., Sachs, G., Yatham, L.N., Asghar, A., Hompland, M., Montgomery, P., Earl, N., Smoot, T.M. & De Veaugh-Geiss, J. (2003). Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60, 392–400.CrossRefGoogle ScholarPubMed
Bschor, T. & Bauer, M. (2006). Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Current Pharmaceutical Design 12, 2985–2992.Google Scholar
Calabrese, J.R., Bowden, C.L., Sachs, G., Yatham, L.N., Behnke, K., Mehtonen, O.P., Montgomery, P., Ascher, J., Paska, W., Earl, N. & DeVeaugh-Geiss, J. (2003). Placebo-controlled 18-month trial of lamot-rigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 64, 1013–1024.CrossRefGoogle ScholarPubMed
Cipriani, A., Pretty, H., Hawton, K. & Geddes, J.R. (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: Systematic review of randomized trials. American Journal of Psychiatry 162, 1805–1819.CrossRefGoogle ScholarPubMed
Collins, J.C. & McFarland, B.H. (2008). Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. Journal of Affective Disorders 107, 23–28.Google Scholar
Dilsaver, S.C., Chen, Y-W., Swann, A.C., Shoaib, A.M., Dilsaver, Y.T. & Krajewski, K.J. (1997). Suicidality panic disorder and psychosis in bipolar depression, depressive-mania and pure mania. Psychiatry Research 73, 47–56.Google Scholar
FDA (US Food and Drug Administration). (2007). Antidepressant use in children, adolescents, and adults. Retrieved February 18, 2009, from http://www.fda.gov/cder/drug/antidepressants/default.htmGoogle Scholar
Goldberg, J.F., Perlis, R.H., Bowden, C.L., Thase, M.E., Miklowitz, D.J., Marangell, L.B., Calabrese, J.R., Nierenberg, A.A. & Sachs, G.S. (2009). Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. American Journal of Psychiatry 166, 173–181.Google Scholar
Goldsmith, S.K., Pellmar, T.C., Kleinman, A.M. & Bunney, W.E. (2002). Reducing Suicide. Institute of Medicine of the US National Academy of Science: Washington, DC.Google Scholar
Goodwin, F.K., Fireman, B., Simon, G.E., Hunkeler, E.M., Lee, J. & Revicki, D. (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. Journal of American Medical Association 290, 1467–1473.CrossRefGoogle ScholarPubMed
Greil, W., Ludwig-Mayerhofer, W., Erazo, N., Schochlin, C., Schmidt, S., Engel, R.R., Czernik, A., Giedke, H., Müller-Oerlinghausen, B., Osterheider, M., Rudolf, G.A., Sauer, H., Tegeler, J. & Wetterling, T. (1997). Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: randomized study. Journal of Affective Disorders 43, 151–161.Google Scholar
Guzzetta, F., Baldessarini, R.J, Tondo, L. & Centorrino, F. (2007). Lithium treatment and suicidal risk in recurrent unipolar major depression. Journal of Clinical Psychiatry 68, 380–383.CrossRefGoogle Scholar
Hammad, T.A., Laughren, T.P. & Racoosin, J.A. (2006). Suicide rates in short-term randomized controlled trials of newer antidepressants. Journal of Clinical Psychopharmacology 26, 203–207Google Scholar
Harris, E.C. & Barraclough, B. (1997). Suicide as an outcome for mental disorders. a meta-analysis. British Journal of Psychiatry 170, 205–228.Google Scholar
Harris, E.C. & Barraclough, B. (1998). Excess mortality of mental disorder. British Journal of Psychiatry 173, 11–53.Google Scholar
Isometsä, E.T., Henriksson, M.M., Aro, H.M., Heikkinen, M.E., Kuoppasalmi, K.I. & Lönnqvist, J.K. (1994). Suicide in major depression. American Journal of Psychiatry 151, 530–536.Google Scholar
Joffe, R.T., Mac Queen, G.M., Marriott, M. & Trevor, Young L. (2004). Prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disorders 6, 62–66.CrossRefGoogle ScholarPubMed
Judd, L.L., Akiskal, H.S., Schettler, P.J., Endicott, J., Maser, J., Solomon, D.A., Leon, A.C., Rice, J.A. & Keller, M.B. (2002). The longterm natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 59, 530–537.CrossRefGoogle ScholarPubMed
Kessing, L.V., Søndergard, L., Kvist, K. & Andersen, P.K. (2005). Suicide risk in patients treated with lithium. Archives of General Psychiatry 62, 860–866.CrossRefGoogle ScholarPubMed
Kessler, R.C., Berglund, P., Borges, G., Nock, M. & Wang, P.S. (2005). Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990–1992 to 2001–2003. Journal of American Medical Association 293, 2487–2495.CrossRefGoogle ScholarPubMed
Koukopoulos, A. & Koukopoulos, A. (1999). Agitated depression as a mixed state and the problem of melancholia. Psychiatric Clinics of North America 22, 547–564.Google Scholar
Maj, M., Pirozzi, R., Magliano, L., Fiorillo, A. & Bartoli, L. (2006). Agitated “unipolar” major depression: prevalence, phenomenology, and outcome. Journal of Clinical Psychiatry 67, 712–719.CrossRefGoogle ScholarPubMed
Meltzer, H.Y., Alphs, L., Green, A.I., Altamura, A.C., Anand, R., Bertoldi, A., Bourgeois, M., Chouinard, G., Islam, M.Z., Kane, J., Krishnan, R., Lindenmayer, J.P., Potkin, S. & International Suicide Prevention Trial Study Group. (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82–91.Google Scholar
Müller-Oerlinghausen, B. (2001). Arguments for the specificity of the antisuicidal effect of lithium. European Archives of Psychiatry and Clinical Neuroscience 251, Suppl. 2, 72–75.Google Scholar
Müller-Oerlinghausen, B., Ahrens, B. & Felber, W. (2006). The suicide-preventive and mortality-reducing effect of lithium. In Lithium in Neuropsychiatry (ed. Bauer, M., Grof, P., Müller-Oerlinghausen, B.), pp 179–192. Informa Healthcare: London.Google Scholar
O’Donovan, C., Garnham, J.S., Hajek, T. & Alda, M. (2008). Antidepressant monotherapy in pre-bipolar depression: predictive value and inherent risk. Journal of Affective Disorders 107, 293–298.CrossRefGoogle ScholarPubMed
Oquendo, M.A., Chaudhury, S.R. & Mann, J.J. (2005). Pharmacotherapy of suicidal behavior in bipolar disorder. Archives of Suicide Research 9, 237–250.CrossRefGoogle ScholarPubMed
Post, R.M., Denicoff, K.D., Leverich, G.S., Altshuler, L.L., Frye, M.A., Suppes, T.M., Rush, A.J., Keck, P.E. Jr, McElroy, S.L., Luckenbaugh, D.A., Pollio, C., Kupka, R. & Nolen, W.A. (2003). Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. Journal of Clinical Psychiatry 64, 680–690.Google Scholar
Rihmer, Z. & Pestality, P. (1999). Bipolar II disorder and suicidal behavior. Psychiatric Clinics of Nord America 22, 667–673.Google Scholar
Roy, A. (2001). Suicide. In Kaplan and Sadock’s Comprehensive Textbook of Psychiatry (ed. Sadock, B.J. and Sadock, V.A.), pp. 2031–2040. Lippincott-Williams & Wilkins: Philadelphia.Google Scholar
Simon, R.I., Hales, R.E. (2006). Textbook of Suicide Assessment and Management. American Psychiatric Press: Washington, DC.Google Scholar
Thies-Flechtner, K., Müller-Oerlinghausen, B., Seibert, W., Walther, A. & Greil, W. (1996). Effect of prophylactic treatment on suicide risk in patients with major affective disorders: Data from a randomized prospective trial. Pharmacopsychiatry 29, 103–107.CrossRefGoogle ScholarPubMed
Tondo, L. & Baldessarini, R.J. (2007). Suicidal risks among 2826 Sardinian major affective disorder patients. Acta Psychiatrica Scandinavica 116, 419428.CrossRefGoogle ScholarPubMed
Tondo, L., Baldessarini, R.J., Hennen, J, Floris, G., Silvetti, F. & Tohen, M. (1998). Lithium treatment and risk of suicidal behavior in bipolar disorder patients. Journal of Clinical Psychiatry 59, 405–414.Google Scholar
Tondo, L, Hennen, J. & Baldessarini, R.J. (2001). Reduced suicide risk with long-term lithium treatment in major affective Illness: A meta-analysis. Acta Psychiatrica Scandinavica 104, 163–172.Google Scholar
Tondo, L., Isacsson, G. & Baldessarini, R.J. (2003). Suicide in bipolar disorder: risk and prevention. CNS Drugs 17, 491–511.CrossRefGoogle ScholarPubMed
Tondo, L., Albert, M.J. & Baldessarini, R.J. (2006). Suicide rates in relations to health care access in the United States: an ecological study. Journal of Clinical Psychiatry 67, 517–523.Google Scholar
Waddington, D. & McKensie, I.P. (1994). Overdose rates in lithium-treated vs. antidepressant-treated outpatients. Acta Psychiatrica Scandinavica 90, 50–52.Google Scholar
Yerevanian, B.I., Koek, R.J. & Mintz, J. (2003). Lithium, anticonvul-sants and suicidal behavior in bipolar disorder. Journal of Affective Disorders 73, 223–228.CrossRefGoogle ScholarPubMed
Zisook, S., Trivedi, M.H., Warden, D., Lebowitz, B., Thase, M.E., Stewart, J.W., Moutier, C., Fava, M., Wisniewski, S.R., Luther, J. & Rush, A.J. (2009). Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR-D study. Journal of Affective Disorders, Epub ahead of print.Google Scholar